MoonLake Immunotherapeutics (MLTX) Non-Current Deffered Revenue (2020 - 2022)

MoonLake Immunotherapeutics' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $4.0 million for Q1 2022.

• On a quarterly basis, Non-Current Deffered Revenue changed 0.0% year-over-year to $4.0 million in Q1 2022; TTM through Mar 2022 was $4.0 million, a 0.0% change from a year earlier, with the FY2021 full-year figure at $4.0 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue held at $4.0 million in Q1 2022 per MLTX's latest filing, from $4.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $4.0 million in Q4 2020 and bottomed at $4.0 million in Q4 2020.
• The 3-year median for Non-Current Deffered Revenue is $4.0 million (2020), against an average of $4.0 million.
• Biggest YoY gain for Non-Current Deffered Revenue was 0.0% in 2021; the steepest drop was 0.0% in 2021.
• Year by year, Non-Current Deffered Revenue stood at $4.0 million in 2020, then changed by 0.0% to $4.0 million in 2021, then changed by 0.0% to $4.0 million in 2022.
• Per Business Quant, the three latest MLTX Non-Current Deffered Revenue figures stand at $4.0 million (Q1 2022), $4.0 million (Q4 2021), and $4.0 million (Q3 2021).